Stifel Financial Corp Has $6.72 Million Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Stifel Financial Corp cut its position in Moderna, Inc. (NASDAQ:MRNAFree Report) by 10.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 67,573 shares of the company’s stock after selling 8,298 shares during the period. Stifel Financial Corp’s holdings in Moderna were worth $6,720,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in MRNA. Vanguard Group Inc. boosted its holdings in shares of Moderna by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 27,658,449 shares of the company’s stock worth $2,856,841,000 after acquiring an additional 196,012 shares in the last quarter. Wellington Management Group LLP raised its position in Moderna by 9.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock valued at $579,572,000 after purchasing an additional 476,201 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Moderna by 77.3% in the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after purchasing an additional 1,690,341 shares in the last quarter. Norges Bank bought a new stake in shares of Moderna during the fourth quarter worth $347,565,000. Finally, Invesco Ltd. increased its stake in shares of Moderna by 19.8% in the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after buying an additional 517,683 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on MRNA shares. UBS Group upped their price target on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. HSBC reissued a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Evercore ISI started coverage on shares of Moderna in a research report on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 price objective for the company. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Finally, Royal Bank of Canada lifted their target price on Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research note on Monday, June 3rd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $128.02.

Get Our Latest Research Report on Moderna

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,296 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total transaction of $210,561.12. Following the sale, the insider now owns 10,623 shares of the company’s stock, valued at $1,725,918.81. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Moderna news, insider Shannon Thyme Klinger sold 1,296 shares of Moderna stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $210,561.12. Following the transaction, the insider now owns 10,623 shares of the company’s stock, valued at $1,725,918.81. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $151.25, for a total transaction of $2,268,750.00. Following the sale, the director now directly owns 1,946,931 shares of the company’s stock, valued at approximately $294,473,313.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 218,245 shares of company stock valued at $26,083,172. Company insiders own 15.70% of the company’s stock.

Moderna Stock Down 2.4 %

Moderna stock opened at $151.01 on Friday. The firm has a market capitalization of $57.87 billion, a price-to-earnings ratio of -9.64 and a beta of 1.54. The company’s 50 day simple moving average is $124.66 and its 200 day simple moving average is $105.79. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNAGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. During the same period last year, the firm posted $0.19 earnings per share. The business’s quarterly revenue was down 91.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Moderna, Inc. will post -7.46 EPS for the current year.

Moderna Company Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Further Reading

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.